Prognostic significance of surgically treated malignant struma ovarii with or without adjuvant thyroid-related therapy: A systematic review and meta-analysis.

IF 2.3 3区 医学 Q2 SURGERY World Journal of Surgery Pub Date : 2024-11-22 DOI:10.1002/wjs.12400
Cameron R Jenkins, Shahab Hajibandeh, Shahin Hajibandeh, David M Scott-Coombes, Richard J Egan
{"title":"Prognostic significance of surgically treated malignant struma ovarii with or without adjuvant thyroid-related therapy: A systematic review and meta-analysis.","authors":"Cameron R Jenkins, Shahab Hajibandeh, Shahin Hajibandeh, David M Scott-Coombes, Richard J Egan","doi":"10.1002/wjs.12400","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>The aims of this study are to determine the long-term overall survival (OS) after surgically treated malignant struma ovarii (MSO) and to evaluate prognostic effect of adjuvant thyroid-related therapy (ATRT) in this setting.</p><p><strong>Methods: </strong>A systematic review in compliance with Preferred Reporting Items for Systematic reviews and Meta-Analyses standards was conducted. MEDLINE, CINAHL, CENTRAL, Scopus, trial registries, and gray literature were searched. Due to rarity of the disease, all case reports including patients with surgically treated MSO were pooled to create a single cohort which was then compared with the eligible case series. The OS and survival time were primary outcomes. The OS was determined using Kaplan-Meier survival statistics, and the predictors of OS were determined using the stepwise Cox proportional-hazards regression model.</p><p><strong>Results: </strong>The study included 376 patients (95 from case reports and 281 from case series). The median age was 44 years; 79% (75/95) were symptomatic. In terms of ATRT, 39% (37/95) received thyroidectomy, 28% (27/95) radioactive iodine, 28% (27/95) hormone suppression therapy, and 55% (52/95) received no therapy. Recurrence occurred in 27% (26/95) with the median time to recurrence of 4 years. The pooled OS was 91% at 10 years and 87% at 20 years. The OS was not predicted by age (p = 0.320), symptomatic status (p = 0.371), follicular histology (p = 0.934), metastatic disease (p = 0.981); omentectomy (p = 0.523), total thyroidectomy (p = 0.371), radioactive iodine therapy (p = 0.285), and thyroid hormone therapy (p = 0.994).</p><p><strong>Conclusions: </strong>Surgically treated MSO may have excellent long-term prognosis with or without ATRT. It is possible that thyroid-specific treatments in MSO constitute overtreatment, with no demonstrable survival benefit. Limitations in the evidence base limit the ability to produce definitive conclusions.</p>","PeriodicalId":23926,"journal":{"name":"World Journal of Surgery","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/wjs.12400","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: The aims of this study are to determine the long-term overall survival (OS) after surgically treated malignant struma ovarii (MSO) and to evaluate prognostic effect of adjuvant thyroid-related therapy (ATRT) in this setting.

Methods: A systematic review in compliance with Preferred Reporting Items for Systematic reviews and Meta-Analyses standards was conducted. MEDLINE, CINAHL, CENTRAL, Scopus, trial registries, and gray literature were searched. Due to rarity of the disease, all case reports including patients with surgically treated MSO were pooled to create a single cohort which was then compared with the eligible case series. The OS and survival time were primary outcomes. The OS was determined using Kaplan-Meier survival statistics, and the predictors of OS were determined using the stepwise Cox proportional-hazards regression model.

Results: The study included 376 patients (95 from case reports and 281 from case series). The median age was 44 years; 79% (75/95) were symptomatic. In terms of ATRT, 39% (37/95) received thyroidectomy, 28% (27/95) radioactive iodine, 28% (27/95) hormone suppression therapy, and 55% (52/95) received no therapy. Recurrence occurred in 27% (26/95) with the median time to recurrence of 4 years. The pooled OS was 91% at 10 years and 87% at 20 years. The OS was not predicted by age (p = 0.320), symptomatic status (p = 0.371), follicular histology (p = 0.934), metastatic disease (p = 0.981); omentectomy (p = 0.523), total thyroidectomy (p = 0.371), radioactive iodine therapy (p = 0.285), and thyroid hormone therapy (p = 0.994).

Conclusions: Surgically treated MSO may have excellent long-term prognosis with or without ATRT. It is possible that thyroid-specific treatments in MSO constitute overtreatment, with no demonstrable survival benefit. Limitations in the evidence base limit the ability to produce definitive conclusions.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
接受或不接受甲状腺相关辅助治疗的恶性卵巢肿的预后意义:系统回顾和荟萃分析。
目的:本研究旨在确定经手术治疗的恶性卵巢肿(MSO)的长期总生存率(OS),并评估甲状腺相关辅助治疗(ATRT)在这种情况下的预后效果:方法:按照系统综述和Meta分析的首选报告项目标准进行系统综述。检索了MEDLINE、CINAHL、CENTRAL、Scopus、试验登记处和灰色文献。由于该疾病的罕见性,所有包含经手术治疗的MSO患者的病例报告都被集中在一起,形成一个单一的队列,然后与符合条件的病例系列进行比较。OS和生存时间是主要结果。OS采用Kaplan-Meier生存统计,OS的预测因素采用逐步Cox比例危害回归模型:研究共纳入376例患者(95例来自病例报告,281例来自系列病例)。中位年龄为 44 岁;79%(75/95)的患者有症状。就 ATRT 而言,39%(37/95)的患者接受了甲状腺切除术,28%(27/95)的患者接受了放射性碘治疗,28%(27/95)的患者接受了激素抑制治疗,55%(52/95)的患者未接受任何治疗。27%(26/95)的患者复发,中位复发时间为4年。10年和20年的总OS分别为91%和87%。年龄(p = 0.320)、无症状状态(p = 0.371)、滤泡组织学(p = 0.934)、转移性疾病(p = 0.981)、网膜切除术(p = 0.523)、甲状腺全切除术(p = 0.371)、放射性碘治疗(p = 0.285)和甲状腺激素治疗(p = 0.994)均无法预测OS:结论:接受手术治疗的MSO无论是否伴有ATRT,长期预后都很好。对MSO进行甲状腺特异性治疗可能会造成过度治疗,但不会带来明显的生存获益。证据基础的局限性限制了得出明确结论的能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
World Journal of Surgery
World Journal of Surgery 医学-外科
CiteScore
5.10
自引率
3.80%
发文量
460
审稿时长
3 months
期刊介绍: World Journal of Surgery is the official publication of the International Society of Surgery/Societe Internationale de Chirurgie (iss-sic.com). Under the editorship of Dr. Julie Ann Sosa, World Journal of Surgery provides an in-depth, international forum for the most authoritative information on major clinical problems in the fields of clinical and experimental surgery, surgical education, and socioeconomic aspects of surgical care. Contributions are reviewed and selected by a group of distinguished surgeons from across the world who make up the Editorial Board.
期刊最新文献
The cumulative risk and severity of postoperative complications in patients with frailty undergoing major emergency abdominal surgery-A prospective cohort study. The introduction of surgical telementoring systems in rural hospitals. The road to research leadership in resource-limited settings is paved with good intentions but poor outcomes. Overall satisfaction following laparoscopic fundoplication for patients with atypical extraesophageal symptoms: A comparative cohort study. Long-term outcomes of active surveillance for low-risk papillary thyroid carcinoma: Progression patterns and tumor calcification.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1